These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38573822)

  • 21. A spotlight on using HIF-PH inhibitors in renal anemia.
    Odawara M; Nishi H; Nangaku M
    Expert Opin Pharmacother; 2024 Jul; 25(10):1291-1299. PubMed ID: 38994698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M; Sudchada P
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
    Maxwell PH; Eckardt KU
    Nat Rev Nephrol; 2016 Mar; 12(3):157-68. PubMed ID: 26656456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?].
    Ryšavá R
    Vnitr Lek; 2022; 68(7):438-443. PubMed ID: 36402568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
    Packer M
    Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
    Nangaku M
    Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?
    Macdougall IC
    Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):399-405. PubMed ID: 35894273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
    Zhao H; Li P; Zhang HL; Jia L
    Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?
    Locatelli F; Del Vecchio L
    Nephrol Dial Transplant; 2020 Jun; 35(6):926-932. PubMed ID: 30844045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current therapeutic approach for anaemia after kidney transplant.
    Nissaisorakarn V; Nissaisorakarn P; Kantachuvesiri S
    Curr Opin Nephrol Hypertens; 2023 Jan; 32(1):35-40. PubMed ID: 36250458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Debate: Are Hydroxylase Inhibitors Stabilizers a Viable Alternative to Erythropoiesis-Stimulating Agents in the Management of Anemia in CKD? CON.
    Wish JB
    Am J Nephrol; 2022; 53(5):366-371. PubMed ID: 35462360
    [No Abstract]   [Full Text] [Related]  

  • 36. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.
    Singh AK
    Am J Nephrol; 2022; 53(5):361-365. PubMed ID: 35462362
    [No Abstract]   [Full Text] [Related]  

  • 38. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
    Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
    Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease.
    Locatelli F; Del Vecchio L; Esposito C; Gesualdo L; Grandaliano G; Ravera M; ; Minutolo R
    J Nephrol; 2024 Apr; 37(3):753-767. PubMed ID: 38705934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs?
    Locatelli F; Del Vecchio L
    J Am Soc Nephrol; 2022 Nov; 33(11):1966-1979. PubMed ID: 36041790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.